Citigroup’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Citigroup’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3,969	Closed	-$92K	–	7869
2020 Q4	$92K	Buy	3,969 +1,270	+47%	+$16.1K	﹤0.01%	5608
2020 Q3	$27K	Sell	2,699 -1,314	-33%	-$17.6K	﹤0.01%	5995
2020 Q2	$60K	Sell	4,013 -2,656	-40%	-$40.9K	﹤0.01%	5924
2020 Q1	$81K	Buy	6,669 +2,546	+62%	+$40.5K	﹤0.01%	5545
2019 Q4	$65K	Buy	4,123 +3,736	+965%	+$47.7K	﹤0.01%	6114
2019 Q3	$5K	Buy	+387	New	+$4.38K	﹤0.01%	7368

Citigroup's PRVL Position: Q1 2021 in Review

Citigroup sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 3,969 shares — an estimated $92K sold.

Citigroup first reported a position in PRVL in Q3 2019 and held it in 6 quarters. The position peaked at $92K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

Citigroup reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Citigroup sold 3,969 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $92K.
Citigroup first reported a position in Prevail Therapeutics Inc. Common Stock in Q3 2019 and held it in 6 quarters.
Citigroup's Prevail Therapeutics Inc. Common Stock position peaked at $92K in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Citigroup's 13F filing for Q1 2021, filed 13 May 2021.